<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859296</url>
  </required_header>
  <id_info>
    <org_study_id>21-000208</org_study_id>
    <nct_id>NCT04859296</nct_id>
  </id_info>
  <brief_title>AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)</brief_title>
  <acronym>ASCENT</acronym>
  <official_title>Analgesic and Appetite-stimulating Effects of Cannabigerol Administered Alone and in Combination With Delta-9-tetrahydrocannabinol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Medicinal Cannabis Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the analgesic, appetite-stimulating, and subjective effects of&#xD;
      cannabigerol (CBG) alone and in combination with THC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of this double-blind, placebo-controlled, within-subject study in healthy,&#xD;
      occasional cannabis smokers is to ascertain the dose-dependent analgesic and&#xD;
      appetite-stimulating effects of ecologically relevant doses of cannabigerol (CBG) alone and&#xD;
      in combination with a sub-analgesic / sub-appetite stimulating, minimally psychoactive dose&#xD;
      of THC and an analgesic, appetite-stimulating, but intoxicating dose of THC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesia</measure>
    <time_frame>7 hours</time_frame>
    <description>Pain threshold and pain tolerance assessed with the Cold Pressor Test - time to report first feeling pain (0-180 seconds) and remove the hand from the cold water (0-180 seconds). Increased duration means increased pain tolerance and pain threshold.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appetite stimulation</measure>
    <time_frame>7 hours</time_frame>
    <description>Subjective ratings of hunger assessed with a visual analog scale (0-100 mm; 0 mm = no effect, 100 mm = maximum possible effect). Higher ratings indicate higher ratings of hunger / appetite stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abuse liability</measure>
    <time_frame>7 hours</time_frame>
    <description>Subject ratings of &quot;Good Drug Effect&quot; as measured using a visual analog scale (0-100 mm; 0 mm = no effect, 100 mm = maximum possible effect). Higher ratings indicate higher ratings of abuse liability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective ratings of intoxication</measure>
    <time_frame>7 hours</time_frame>
    <description>Subject ratings of &quot;High&quot; as measured using a visual analog scale (0-100 mm; 0 mm = no effect, 100 mm = maximum possible effect). Higher ratings indicate higher ratings of intoxication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective ratings of pain</measure>
    <time_frame>7 hours</time_frame>
    <description>Subject ratings of Painfulness and Bothersomeness of the Cold Pressor Test. Scale is from 0 (Not painful / bothersome at all) to 10 (The most painful / bothersome feeling imaginable), higher ratings indicate greater painfulness and bothersomeness.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pain</condition>
  <condition>Appetite Loss</condition>
  <condition>Abuse, Drug</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg CBG, 0 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low strength CBG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg CBG, 0 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High strength CBG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg CBG, 0 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low strength THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0 mg CBG, 5 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High strength THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0 mg CBG, 30 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low strength CBG + Low strength THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg CBG + 5 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low strength CBG + High strength THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg CBG + 15 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High strength CBG + Low strength THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg CBG + 5 mg THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High strength CBG + High strength THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg CBG + 15 mg THC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaporized placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low CBG</intervention_name>
    <description>Vaporized CBG (5 mg)</description>
    <arm_group_label>Low strength CBG</arm_group_label>
    <arm_group_label>Low strength CBG + High strength THC</arm_group_label>
    <arm_group_label>Low strength CBG + Low strength THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High CBG</intervention_name>
    <description>Vaporized CBG (15 mg)</description>
    <arm_group_label>High strength CBG</arm_group_label>
    <arm_group_label>High strength CBG + High strength THC</arm_group_label>
    <arm_group_label>High strength CBG + Low strength THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low THC</intervention_name>
    <description>Vaporized THC (5 mg)</description>
    <arm_group_label>High strength CBG + Low strength THC</arm_group_label>
    <arm_group_label>Low strength CBG + Low strength THC</arm_group_label>
    <arm_group_label>Low strength THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High THC</intervention_name>
    <description>Vaporized THC (15 mg)</description>
    <arm_group_label>High strength CBG + High strength THC</arm_group_label>
    <arm_group_label>High strength THC</arm_group_label>
    <arm_group_label>Low strength CBG + High strength THC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant and non-lactating females aged 21-55 years&#xD;
&#xD;
          -  Report monthly use of cannabis (â‰¤1 day per week) over the 6 months prior to screening,&#xD;
&#xD;
          -  Not currently seeking treatment for their cannabis use&#xD;
&#xD;
          -  Have a Body Mass Index from 18.5 - 34kg/m2.&#xD;
&#xD;
          -  Able to perform all study procedures&#xD;
&#xD;
          -  Must be using a contraceptive (hormonal or barrier methods)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meeting DSM-V criteria for moderate-severe Cannabis Use disorder (CUD) or any&#xD;
             substance use disorder other than nicotine, caffeine, or mild CUD&#xD;
&#xD;
          -  Any other Axis I disorder&#xD;
&#xD;
          -  Report using other illicit drugs in the prior 4 weeks&#xD;
&#xD;
          -  Current use of prescription analgesics, or any medications that may affect study&#xD;
             outcomes&#xD;
&#xD;
          -  If medical history, physical and psychiatric examination, or laboratory tests&#xD;
             performed during the screening process are not within the normal range and / or reveal&#xD;
             any significant illness (e.g., hypertension) as judged by the study physician and to&#xD;
             put the participant at greater risk of experiencing adverse events due to completion&#xD;
             of study procedures.&#xD;
&#xD;
          -  Current pain&#xD;
&#xD;
          -  Pregnancy is exclusionary due to the possible effects of the study medication on fetal&#xD;
             development.&#xD;
&#xD;
          -  History of an allergic reaction or adverse reaction to cannabis is exclusionary.&#xD;
&#xD;
          -  History of respiratory illness or current respiratory illness&#xD;
&#xD;
          -  Currently enrolled in another research protocol&#xD;
&#xD;
          -  Not using a contraceptive method (hormonal or barrier methods)&#xD;
&#xD;
          -  Insensitivity to the cold water stimulus of the Cold Pressor Test&#xD;
&#xD;
          -  Any disorders that might make cannabis administration hazardous are exclusionary, as&#xD;
             determined by the evaluating physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziva D Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziva D Cooper, PhD</last_name>
    <phone>310-206-9942</phone>
    <email>zcooper@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Acebo</last_name>
    <phone>310-983-3417</phone>
    <email>vacebo@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ziva D Cooper, PhD</last_name>
      <phone>310-206-9942</phone>
      <email>zcooper@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Acebo</last_name>
      <phone>310-983-3417</phone>
      <email>vacebo@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ziva D Cooper, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Ziva D. Cooper, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>Pain</keyword>
  <keyword>Appetite</keyword>
  <keyword>THC</keyword>
  <keyword>Cannabigerol</keyword>
  <keyword>CBG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

